These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 3687149)

  • 21. Effect of oral bismuth subsalicylate on Campylobacter pylori and on healing and relapse rate of peptic ulcer.
    Eberhardt R; Kasper G
    Rev Infect Dis; 1990; 12 Suppl 1():S115-9. PubMed ID: 2406852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [What is safe in the treatment of Campylobacter pylori-induced gastritis and Campylobacter pylori-associated peptic ulcer?].
    Menge H
    Internist (Berl); 1988 Nov; 29(11):745-54. PubMed ID: 3069787
    [No Abstract]   [Full Text] [Related]  

  • 23. Colloidal bismuth subcitrate in peptic ulcer disease.
    Tytgat GN
    S Afr Med J; 1986 Jul; 70(1):31-3. PubMed ID: 3523793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Morphologic change in Campylobacter pylori associated gastritis in and following successful antibacterial therapy].
    Rühl GH; Börsch G
    Pathologe; 1989 Jan; 10(1):64-5. PubMed ID: 2922381
    [No Abstract]   [Full Text] [Related]  

  • 25. Campylobacter pylori and its role in peptic ulcer disease.
    Tytgat GN; Rauws EA
    Gastroenterol Clin North Am; 1990 Mar; 19(1):183-96. PubMed ID: 2184128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori.
    Marshall BJ; Goodwin CS; Warren JR; Murray R; Blincow ED; Blackbourn SJ; Phillips M; Waters TE; Sanderson CR
    Lancet; 1988 Dec 24-31; 2(8626-8627):1437-42. PubMed ID: 2904568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Likelihood of relapse of duodenal ulcer after initial treatment with cimetidine or colloidal bismuth subcitrate.
    Miller JP; Hollanders D; Ravenscroft MM; Tweedle DE; Martin DF
    Scand J Gastroenterol Suppl; 1982; 80():39-42. PubMed ID: 6761851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of Campylobacter pylori-associated antral gastritis in children with bismuth subsalicylate and ampicillin.
    Drumm B; Sherman P; Chiasson D; Karmali M; Cutz E
    J Pediatr; 1988 Nov; 113(5):908-12. PubMed ID: 3183851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Characteristics of the effects of de-nol on the course of erosive-ulcerative lesions of the esophagus, stomach and duodenum associated with Helicobacter pylori].
    Grebenev AL; Miagkova LP; Golochevskaia VS; Lapina TL; Sklianskaia OA
    Klin Med (Mosk); 1995; 73(2):34-7. PubMed ID: 7609414
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical indications and efficacy of colloidal bismuth subcitrate.
    Lambert JR
    Scand J Gastroenterol Suppl; 1991; 185():13-21. PubMed ID: 1957121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topically active drugs in the treatment of peptic ulcers. Focus on colloidal bismuth subcitrate and sucralfate.
    Bianchi Porro G; Parente F
    J Clin Gastroenterol; 1992 Apr; 14(3):192-8. PubMed ID: 1348753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Morphology of the gastric mucosa in patients with duodenal ulcer treated with bismuth-containing drugs].
    Mach T
    Folia Med Cracov; 1995; 36(1-4):53-75. PubMed ID: 8834668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial.
    Humphreys H; Bourke S; Dooley C; McKenna D; Power B; Keane CT; Sweeney EC; O'Moráin C
    Gut; 1988 Mar; 29(3):279-83. PubMed ID: 3356357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of Campylobacter pylori does not alter gastric acid secretion.
    Montbriand JR; Appelman HD; Cotner EK; Nostrant TT; Elta GH
    Am J Gastroenterol; 1989 Dec; 84(12):1513-6. PubMed ID: 2596452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antibacterial treatment of Campylobacter pylori-associated gastritis and peptic ulcer].
    Andreasen JJ; Ringsdal VS
    Ugeskr Laeger; 1989 Apr; 151(17):1030-3. PubMed ID: 2734863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy of colloid bismuth subcitrate (De-Nol) in gastropathies induced by nonsteroid anti-inflammatory drugs: an open controlled 4-week trial].
    Karateev AE; Nasonov EL; Radenska-Lopovok SG
    Ter Arkh; 2005; 77(2):46-9. PubMed ID: 15807452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Ulcer symptoms without demonstration of ulcer: causative therapy with demonstration of Helicobacter pylori].
    Kobler E; Müller B; Wüst W
    Schweiz Rundsch Med Prax; 1990 Mar; 79(13):398-9. PubMed ID: 2320815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Site-and cytoprotective drugs in the short-term treatment of peptic ulcer. What is their current role?
    Bianchi Porro G; Parente F
    Ital J Gastroenterol; 1990; 22 Suppl 1():5-10. PubMed ID: 1983422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate.
    O'Riordan T; Mathai E; Tobin E; McKenna D; Keane C; Sweeney E; O'Morain C
    Gut; 1990 Sep; 31(9):999-1002. PubMed ID: 2210469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Omeprazole/amoxicillin versus triple therapy for Helicobacter pylori in duodenal ulcer disease: two-year follow-up of a prospective randomized study.
    Labenz J; Stolte M; Peitz U; Tillenburg B; Köhl H; Becker T; Börsch G
    Z Gastroenterol; 1995 Oct; 33(10):590-3. PubMed ID: 7502551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.